An Open-Label, Randomized, Crossover, Repeat-Dose Study to Evaluate the Steady-State Pharmacokinetic Profile of the Final Fixed Dose Combination (FDC) Formulation of COREG CR and Lisinopril as Compared to COREG CR in Subjects With Essential Hypertension.

Trial Profile

An Open-Label, Randomized, Crossover, Repeat-Dose Study to Evaluate the Steady-State Pharmacokinetic Profile of the Final Fixed Dose Combination (FDC) Formulation of COREG CR and Lisinopril as Compared to COREG CR in Subjects With Essential Hypertension.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2010

At a glance

  • Drugs Carvedilol/lisinopril (Primary) ; Carvedilol
  • Indications Essential hypertension
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 May 2009 Actual initiation date changed from Sep 2007 to Oct 2007 as reported by ClinicalTrials.gov.
    • 11 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top